Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.

Pui, Ching Hon; Rubnitz, Jeffrey E.; Hancock, Michael L.; Downing, James R.; Raimondi, Susana C.; Rivera, Gaston K.; Sandlund, John T.; Ribeiro, Raul C.; Head, David R.; Relling, Mary V.; Evans, William E.; Behm, Frederick G.

doi:10.1200/jco.1998.16.12.3768

Cited by 109 publications

(78 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T cell patients are less likely to be CD34 positive, 31 more likely to be older, be CNS positive at diagnosis, have L2 morphology and a higher initial white count. Null cell patients tend to be less than 2 years old and more commonly CD13 and 33 positive, as well as being CD10 negative.…”

Section: Figurementioning

confidence: 99%

Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI)

Hann

Richards²,

Eden

et al. 1998

Leukemia

View full text Add to dashboard Cite

Despite many years of meticulous immunophenotyping of childhood acute lymphoblastic leukaemia (ALL) cases the prognostic significance of some subtypes remains unclear. The Medical Research Council UKALLXI trial (1990)(1991)(1992)(1993)(1994)(1995)(1996) in which uniform treatment has been given to 2090 children with ALL below the age of 18 years and above the age of 1 year, has afforded the opportunity to review these issues. Children with ALL of mature B cell type were not entered into this trial. Immunophenotype analysis was performed in each individual trial centre, but results were centrally reviewed in all cases, and were both available and considered adequate in 1934 (93%) of the first 2090 patients entered. The main diagnostic categories were early pre-B or null reported in 60 cases (3.1%), common ALL in 1242 (64.2%), pre-B in 252 (13.0%), 'common' or pre-B in 172 (8.9%) and T cell in 207 (10.7%) cases. Children with T cell disease were significantly more likely to be over the age of 10 years, with central nervous system disease at diagnosis and to be CD34 negative. They also had a higher incidence of high white cell count and were more likely to be of the FrenchAmerican-British (FAB) L2 morphological subtype. Patients with 'null' cell disease tended to be less than 2 years or greater than 10 years of age, and CD13 and CD33 positive. CD10 was associated with lower white cell count (WBC) at diagnosis, younger age and FAB L1 morphological subtype. The presence of cytoplasmic immunoglobulin in pre-B cells was not associated with any specific clinical or laboratory features. CD34 positivity was less common in T cell patients and was associated with low WBC. Disease-free survival (DFS) and 95% confidence intervals (CI) at 5 years from diagnosis was 52% (95% CI: 44-59%) for T cell disease, 58% (95% CI: 43-73%) for early pre-B (or null cell) disease and 65% (95% CI: 62-68%) for common or pre-B disease; there being no significant difference between common and pre-B disease with regard to disease outcome. Patients with T cell disease had a worse prognosis than any other immunophenotype group (P Ͻ 0.00005). However this worse outcome was no longer significant after allowing for the other principal prognostic factors of age, gender and white cell count at diagnosis except for the very small number with WBC Ͻ20 × 10 9 /l and T cell disease. Those with CD10-positive leukaemia did better than those who were CD10 negative (P Ͻ 0.00005), with DFS at 5 years 64% (95% CI: 62-67%) for positive vs 56% (95% CI: 49-62%) for CD10 negative. CD10 positivity did not have independent significance when white count, gender and age were taken into account. CD13, CD33, and cytoplasmic positivity carried no prognostic significance. Keywords: immunophenotype; prognosis; acute lymphoblastic leukaemia (ALL); children IntroductionImmunological heterogeneity of ALL has been recognised for many years. ing which time the use of standardised panels of antibodies has permitted allocation of more than 98% of leukaemias to their respective lineage...

show abstract

Section: Figurementioning

confidence: 99%

Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI)

Hann

Richards²,

Eden

et al. 1998

Leukemia

View full text Add to dashboard Cite

show abstract

“…Studies on the expression of CD10 and CD34, alone or in combination, as a prognostic factor, found discrepancies [6,7,10,10,22,23]. These discrepancies may be dependent upon sensitivity of the immunophenotyping, upon patient variables, or upon differences in treatment protocols.…”

Section: Discussionmentioning

confidence: 99%

“…In B-lineage ALL, the percentage of cells expressing CD10 decreases in more mature forms [1,2]. Positive CD10 expression was associated with favorable clinical outcome [13]. In addition, lower white blood cell count (WBC), younger age, and subtype FAB L1 were associated with higher expression of CD10 [14].…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4][5] CD10 and CD34 are surface markers that have been reported to have prognostic relevance in childhood acute lymphoblastic leukemia (ALL), but the results were conflicting [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…The clinical significance of CD34 expression has been debated. It appears that the prognostic value depends on the type of leukemia and protocol used [7,[17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Detection of CD10, CD34 and their combined expression on Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia

Hirshoren¹,

Veerman²,

Sutaryo³

et al. 2012

J Cancer Ther Res

View full text Add to dashboard Cite

show abstract

CD13

Riemann

2002

Wiley Encyclopedia of Molecular Medicine

View full text Add to dashboard Cite

Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.

Abstract: Even though blast cell expression of myeloid-associated antigen expression shows significant associations with specific genetic abnormalities, it lacks prognostic value in childhood ALL.

Cited by 109 publications

References 26 publications

Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI)

Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI)

Detection of CD10, CD34 and their combined expression on Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia

CD13

Contact Info

Product

Resources

About